Identification of people with heterozygous familial hypercholesterolemia

Current Opinion in Lipidology

Volumn 23, Issue 4, 2012, Pages 282-289

  Haase, Annie ^a   Goldberg, Anne C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cascade screening; familial hypercholesterolemia; genetic testing; universal screening

Indexed keywords

APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEART INFARCTION; HETEROZYGOTE; HUMAN; HYPOTHYROIDISM; IMMUNIZATION; LIPID ANALYSIS; NEPHROTIC SYNDROME; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; XANTHOMA;

COST-BENEFIT ANALYSIS; GENETIC TESTING; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC;

EID: 84863956322     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283556c33     Document Type: Review

References (42)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. pp. 2863-2913.
2. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 Suppl.):S9-S17.
3. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168:1-14.
4. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29:2625-2633.
5. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423.
6. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4:214-225.
7. Varret M, Abifadel M, Rabè s J-P, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 2008; 73:1-13.
8. Humphries SE, Norbury G, Leigh S, et al. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 2008; 19:362-368.
9. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011; 12:221-263.
10. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011; 97:1175-1181.
11. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209:189-194.
12. Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5:e9220.
13. Datta BN, McDowell IFW, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol 2010; 21:366-371.
14. Williams RR, Hunt SC, Schumacher C, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
15. HEART UK. Diagnostic criteria for Familial Hypercholesterolaemia using Simon Broome register. http://www.heartuk.org.uk/HealthProfessionals/downloads/ 05-advice-and-information/HUK-AS04-Diagnostic.pdf. [Accessed 21 April 2012].
16. DeMott K, Nherera L, Shaw EJ, et al. National Institute for Health and Clinical Excellence Clinical Guidelines and Evidence Review for Familial Hypercholesterolemia: the identification and management of adults and children with familial hypercholesterolemia (Clinical guideline 71).London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
17. World Health Organization. Familial hypercholesterolaemia. Report of a second WHO consultation. Geneva: World Health Organization; 1999.
18. Hopkins PN. Defining the challenges of familial hypercholesterolemia: introduction. J Clin Lipidol 2010; 4:342-345.
19. Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. J Clin Lipidol 2010; 4:338-341.
20. Aarden E, Van Hoyweghen I, Horstman K. The paradox of public health genomics: definition and diagnosis of familial hypercholesterolaemia in three European countries. Scand J Public Health 2011; 39:634-639.
21. Chiou K-R, Charng M-J, Chang H-M. Array-based resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis 2011; 216:383-389.
22. Dusková L, Kopecková L, Jansová E, et al. An APEX-based genotyping microarray for the screening of 168 mutations associated with familial hypercholesterolemia. Atherosclerosis 2011; 216:139-145.
23. Palacios L, Grandoso L, Cuevas N, et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 2012; 221:137-142.
24. van der Graaf A, Avis HJ, Kusters DM, et al. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011; 123:1167-1173.
25. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (Suppl. 1):S1-S44.
26. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:133-140.
27. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S18-S29.
28. Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S30-S37.
29. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S38-S45.
30. Goldberg AC, Robinson JG, Cromwell WC, et al. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 Suppl.):S46-S51.
31. Daniels SR, Greer FR; and the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198-208.
32. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128(Suppl. 5):S213-S256.
33. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA 2012; 307:257-258.
34. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA 2012; 307:259-260.
35. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patent organization. Atherosclerosis 2011; 218:272-280.
36. Kusters DM, De Beaufort C, Widhalm K, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child 2012; 97:272-276.
37. Wald DS, Kasturiratne A, Godoy A, et al. Child-parent screening for familial hypercholesterolemia. J Pediatr 2011; 159:865-867.
38. Morris JK, Wald DS, Wald NJ. The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet Part A 2012; 158A:78-84.
39. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116:664-668.
40. Leren TP, Berge KE. Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated. PLoS ONE 2011; 6:e16721; doi:10.1371/journal.pone.0016721.
41. National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
42. Kwiterovich PO. Clinical implications of the molecular basis of familial hypercholesterolemia and other inherited dyslipidemias. Circulation 2011; 123:1153-1155.